HIV pre-exposure prophylaxis, or PrEP, is currently only available in the form of a daily oral pill. But, researchers are working to increase options for administering PrEP, including taking it as a long-acting injection through a drug called cabotegravir.
In our Research Roundtable series, FHI 360 Principal Economist Annette Brown speaks with FHI 360 experts to hear about their successes and lessons learned from recently published research. In this episode, Betsy Tolley, Director of Behavioral, Epidemiological and Clinical Sciences Research at FHI 360, joins to discuss the promising new findings on the acceptability and effectiveness of a long-acting injectable PrEP option among women.
Read the full research paper, which was made possible by the HIV Prevention Trials Network (HPTN 077): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813716/.
